CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
about
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsCYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsIn vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohortNevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Pharmacogenomics of antimicrobial agents.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successModest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.PharmGKB summary: Efavirenz pathway, pharmacokineticsPharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Individualization of antiretroviral therapy.Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamicsGenome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEFV/FTC/TDF-associated hepatotoxicity: a case report and review.Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.Priority pharmacogenetics for the African continent: focus on CYP450.Pharmacogenetics of antiretroviral therapy.Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Class-specific relative genetic contribution for key antiretroviral drugs.Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Impact of pharmacogenetics on CNS side effects related to efavirenz.
P2860
Q21245026-89DB0B58-2FDC-422B-AC61-3867C5597F5FQ27012807-E6400A1B-F921-4538-AD39-968C9B3A7E08Q28293875-BD39499C-D9F7-4B02-BC20-8026F74A6CD7Q33623024-C140E62D-FE55-4592-BB39-A801E4CA2D68Q33798516-D80041E6-F233-4C61-912E-57893AE80AB8Q33809438-8EBBEC96-6A48-4D7B-AE23-43FE4FBA74DCQ33821729-330A6E45-50BC-4DD3-BD64-68E8840C880DQ33861268-1A18AFAB-6E3D-4A26-9234-5A1704AF764AQ33909996-917EAEAF-6C2D-4A5E-BFAF-CA7534167753Q34015667-9C7FBF02-4B82-45FE-B5E1-EF2EE1FD4BF9Q34571645-93440477-65ED-4803-B76A-E4A0D49F69F3Q34710641-DA0B51A3-9703-4113-A804-96CB0A9C2799Q34737523-2DB9C924-6287-4B13-9382-E5898DE68847Q34756398-BE0886B4-A7BF-4964-8008-D99740D94099Q34977413-04FEDC00-F997-4BCF-A728-9B98E724F7F4Q35043700-39ED941C-017F-4397-B4BC-6D6A4C991FFAQ35065867-C552D57C-3CA6-4DBB-8672-7E6DADE49720Q35364120-302DB944-3134-4CF9-A8F9-7AAA66F87D20Q35518558-D8F67293-B290-4956-870B-5E3A312D970DQ35547723-4F28FD14-DDC1-4201-9690-2F0D593636A3Q35706069-D351D02B-84C5-4C44-98B3-260C31F1B8C1Q35846143-C3C23D59-34FD-40FB-85A6-2BE376E2A733Q36079108-454D0ACB-7B0A-42EC-A1C9-732A6EF6CD7FQ36441423-E187FF53-82E1-405A-B87E-30EED8A98BFEQ36468146-0A5C15DD-90BB-4144-9BF4-0347DE2D361DQ36693543-F5A9BFD9-8DD2-4B1F-8FA6-9FBBF87DB4C7Q36734592-A41259A9-AF3B-4366-B622-03495247FA55Q37139458-017F3C34-99D1-40ED-B228-B9517DDAE061Q37171678-B4F4993D-1111-4D26-ABFE-9DA8DDD6717EQ37325589-07A774F1-387B-43D6-B956-7362420C6DE8Q38051400-8360364D-018B-4753-AD48-BCD8C12C01CDQ38164430-C83223FE-72F5-4A08-956C-4D0ACBAF6F52Q38188600-E5076AD7-CAEA-4503-97F5-4305A4496916Q38221179-FD4DE512-4EC6-4DB7-8650-849FA4B5B672Q38267710-24BA9528-E3F7-48B9-A670-5E25D3E4F531Q38815352-D5C2557B-925D-43ED-8480-F5EBCD966266Q38957969-2CFE7552-D4FB-4025-A192-FA5C9339F456Q38980007-863B41DD-E9E6-42BE-98AE-4165F9784AF3Q38987587-015D6193-AEE2-4022-9E38-C2A441912FCCQ39383647-52AD5553-C064-4C56-8679-5F0EC98084E9
P2860
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@ast
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@en
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@nl
type
label
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@ast
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@en
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@nl
prefLabel
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@ast
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@en
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@nl
P2093
P2860
P1433
P1476
CYP2B6, CYP2A6 and UGT2B7 gene ...... ation in HIV-infected patients
@en
P2093
Awewura Kwara
Ernest Kenu
Kwamena W C Sagoe
Margaret Lartey
Michael H Court
P2860
P304
P356
10.1097/QAD.0B013E3283319908
P407
P577
2009-10-23T00:00:00Z